Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European Funding Boosts Research into Breast Cancer

29.04.2005


As cancer is the main cause of death among women aged 35 to 64 the EU’s Sixth Framework Programme (FP6) has agreed to provide seven million euros for a new Network of Excellence called TRANS-BIG, aimed at addressing the treatment of breast cancer.



TRANS-BIG aims to refine the diagnosis of breast cancer in a way that will enable specialists reduce the number of women being over treated by better identification of those who will benefit from treatment.

“Under the present system many patients are over treated while only a few derive a considerable benefit”, says Dr Robert Leonard from the South West Wales Cancer Institute. “By refining the prognosis for a better definition of who needs treatment we hope to significantly reduce the proportion of women receiving unnecessary chemotherapy and reduce their exposure to toxicity and harmful long-term side effects. At the same time, this will considerably reduce the cost of breast cancer therapy and its burden on European health care systems.


“Indeed, two decades of clinical trials have shown that although chemotherapy increases the survival rate from 2 to 12 per cent, it can also be the cause of secondary cancers, cardiac toxicity, early menopause and a reduction in cognitive functions.”

The TRANS-BIG Network of Excellence, based on the principles of translational research - ’bench to bedside’ and ’bedside to bench’ - will tackle the fragmentation which currently exists in this field of research and accelerate the clinical applications of biological discoveries.

With 39 partners from 21 countries the TRANS-BIG consortium has the critical mass expertise needed to create a fully coherent research force of leading specialists in Europe. This in itself will help overcome the existing fragmentation of effort and give Europe the competitive approach it needs to take the lead in breast cancer therapy internationally.

The first target of TRANS-BIG is the development of its first trial - MINDACT (Microarray for Node Negative Disease may avoid Chemotherapy) - using microarrays to identify the specific molecular make up (’signature’) of a tumour. Although still in its infancy, this technology is expected to allow for a better selection of the patients that actually do need chemotherapy.

“We believe that the results of MINDACT will show that using the new technology to assess risk will result in fewer women being treated unnecessarily”, added Dr Leonard. “This, in turn, will mean that fewer women will suffer from the unpleasant side effects of chemotherapy. Not only will the overall quality of life of breast cancer patients be improved, but the health care costs associated with such cancer treatment will be reduced as well, thus providing a significant benefit to society. Additionally, by more accurately choosing patients who do need chemotherapy the final outcome in terms of survival is expected to be better.

By conducting translational research in an integrated way, the project will ensure that the best facilities from the leading cancer research and treatment institutes will be shared, thus decreasing cost and increasing effectiveness.

“Improving the way we diagnose and treat breast cancer is crucial if we are to prevent many women receiving unnecessary, and costly, chemotherapy treatment in the future”, says Claire Horton, FP6UK’s National Contact Point for ’Life sciences, genomics and biotechnology for health. “The fight against cancer is a priority issue for the EU as it is estimated that our increasingly ageing population will lead to an extra 250,000 cancer diagnoses every year in Europe by 2020.

“The current Framework Programme (FP6) runs until 2006 and organisations wanting free information on how to access some of the 19 billion euros available should log on to http://fp6uk.ost.gov.uk or call central telephone support on 0870 600 6080.”

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Health and Medicine:

nachricht 'On-off switch' brings researchers a step closer to potential HIV vaccine
30.03.2017 | University of Nebraska-Lincoln

nachricht Cardiac diseases: when less is more
30.03.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

NASA laser communications to provide Orion faster connections

30.03.2017 | Physics and Astronomy

Reusable carbon nanotubes could be the water filter of the future, says RIT study

30.03.2017 | Studies and Analyses

Unique genome architectures after fertilisation in single-cell embryos

30.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>